

GSK plc (the 'Company')
Vesting of Performance Share Plan Awards

This notification sets out the vesting details of awards over Ordinary Shares and American Depositary Shares ('ADSs') made to Persons Discharging Managerial Responsibilities ('PDMRs') and their Persons Closely Associated ('PCAs') in February 2021 under the GlaxoSmithKline 2017 Performance Share Plan ('PSP'), which were subject to relevant business performance conditions, and the subsequent sale of ordinary shares and ADSs to meet tax liabilities. Awards were made in 2021 and the three-year performance period commenced on 1 January 2021 and ended on 31 December 2023. The vested shares for the Executive Directors are now subject to an additional two-year vesting period.

The performance measure vesting details for those PDMRs who received awards in 2021 are set out in the following table.

		Outcome and Vesting Level	
Portion of the Award	Measure and Outcome	% of maximum	% of award
30%	<p>Adjusted Free Cash Flow - For the three years ending 31 December 2023, the Company achieved Adjusted Free Cash Flow calculated in accordance with the principles for the measure of £9.81bn, which is above the revised amount of £6.54bn required for maximum vesting.</p> <p>Adjustments to the original target and vesting schedule were set out in detail in the 2022 Annual Report.</p>	100	30.00
30%	<p>Total Shareholder Return - For the three-year period the Company's Total Shareholder Return ranked 9th, which is below the threshold vesting level against a comparator group of 10 global pharmaceutical companies including GSK.</p>	0	0.00
20%	<p>Innovation Sales - For the three-year period, the Company achieved revenues from new products calculated in accordance with the principles for the measure of £18.651bn, which is slightly below the level of £18.667bn required for 100% vesting. The threshold vesting level was £15.273bn.</p>	99.77	19.95
20%	<p>Pipeline Progress - measure is equally weighted between:</p> <ul style="list-style-type: none"> - Pivotal trial starts - Major regulatory approvals 	100 100	10.00 10.00
	Total vesting for 2021 award Lapsed	69.95 30.05	69.95

The notifications that follow are for awards made to PDMRs and their PCAs and detail the PSP conditional awards that vested, including dividends accrued, on 9 February 2024. The balance of the award made to each PDMR and PCA has lapsed.

The closing prices of Ordinary Shares and of ADSs of GSK plc on the vesting date were £16.60 and \$41.91.

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')					
a)	Name	Emma Walmsley				
b)	Position/status	Chief Executive Officer				
c)	Initial notification/ amendment	Initial notification				
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a)	Name	GSK plc				
b)	LEI	5493000HZTVUYLO1D793				
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted					
a)	Description of the financial instrument	Ordinary Shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63				
b)	Nature of the transaction	The number of Ordinary Shares vesting on awards granted in 2021 under the Company's 2017 Performance Share Plan. These shares are now subject to a two-year hold.				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>£0.00</td> <td>441,309</td> </tr> </tbody> </table>	Price(s)	Volume(s)	£0.00	441,309
Price(s)	Volume(s)					
£0.00	441,309					
d)	Aggregated information Aggregated volume Price	N/A (single transaction)				
e)	Date of the transaction	2024-02-09				
f)	Place of the transaction	N/A				

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	Diana Conrad
b)	Position/status	Chief People Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted	
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The number of Ordinary Shares vesting on awards granted in 2021 under the Company's 2017 Performance Share Plan

c)	Price(s) and volume(s)	Price(s) £0.00	Volume(s) 89,414
d)	Aggregated information Aggregated volume Price	N/A (single transaction)	
e)	Date of the transaction	2024-02-09	
f)	Place of the transaction	N/A	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Diana Conrad	
b)	Position/status	Chief People Officer	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2021 under the Company's 2017 Performance Share Plan	
c)	Price(s) and volume(s)	Price(s) £16.6055	Volume(s) 47,864
d)	Aggregated information Aggregated volume Price	N/A (single transaction)	
e)	Date of the transaction	2024-02-09	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	James Ford
b)	Position/status	SVP and Group General Counsel, Legal and Compliance

c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	The number of Ordinary Shares vesting on awards granted in 2021 under the Company's 2017 Performance Share Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£0.00	139,077
d)	Aggregated information	N/A (single transaction)	
	Aggregated volume Price		
e)	Date of the transaction	2024-02-09	
f)	Place of the transaction	N/A	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	James Ford	
b)	Position/status	SVP and Group General Counsel, Legal and Compliance	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2021 under the Company's 2017 Performance Share Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£16.6055	65,367
d)	Aggregated information	N/A (single transaction)	
	Aggregated volume Price		

d)	Aggregated information Aggregated volume Price	N/A (single transaction)
e)	Date of the transaction	2024-02-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')					
a)	Name	Sally Jackson				
b)	Position/status	SVP, Global Communications and CEO Office				
c)	Initial notification/ amendment	Initial notification				
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a)	Name	GSK plc				
b)	LEI	5493000HZTVUYLO1D793				
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted					
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63				
b)	Nature of the transaction	The number of Ordinary Shares vesting on awards granted in 2021 under the Company's 2017 Performance Share Plan				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>£0.00</td> <td>52,746</td> </tr> </tbody> </table>	Price(s)	Volume(s)	£0.00	52,746
Price(s)	Volume(s)					
£0.00	52,746					
d)	Aggregated information Aggregated volume Price	N/A (single transaction)				
e)	Date of the transaction	2024-02-09				
f)	Place of the transaction	N/A				

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	Sally Jackson
b)	Position/status	SVP, Global Communications and CEO Office
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793

3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted	
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2021 under the Company's 2017 Performance Share Plan
c)	Price(s) and volume(s)	Price(s)
		Volume(s)
		£16.6055
		24,791
d)	Aggregated information	N/A (single transaction)
	Aggregated volume	
	Price	
e)	Date of the transaction	2024-02-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	Dylan Jackson
b)	Position/status	PCA of Ms S Jackson (SVP, Global Communications and CEO Office)
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted	
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The number of Ordinary Shares vesting on awards granted in 2021, 2022 and 2023 under the Company's 2017 Performance Share Plan
c)	Price(s) and volume(s)	Price(s)
		Volume(s)
		£0.00
		7,642
d)	Aggregated information	N/A (single transaction)
	Aggregated volume	
	Price	
e)	Date of the transaction	2024-02-09
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Dylan Jackson	
b)	Position/status	PCA of Ms S Jackson (SVP, Global Communications and CEO Office)	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2021, 2022 and 2023 under the Company's 2017 Performance Share Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£16.6055	3,592
d)	Aggregated information	N/A (single transaction)	
	Aggregated volume Price		
e)	Date of the transaction	2024-02-09	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Luke Miels	
b)	Position/status	Chief Commercial Officer	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	The number of Ordinary Shares vesting on awards granted in 2021 under the Company's 2017 Performance Share Plan	

	transaction	under the Company's 2017 Performance Share Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£0.00	195,810
d)	Aggregated information	N/A (single transaction)	
	Aggregated volume Price		
e)	Date of the transaction	2024-02-09	
f)	Place of the transaction	N/A	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Luke Miels	
b)	Position/status	Chief Commercial Officer	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2021 under the Company's 2017 Performance Share Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£16.6055	13,864
d)	Aggregated information	N/A (single transaction)	
	Aggregated volume Price		
e)	Date of the transaction	2024-02-09	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Shobie Ramakrishnan	
b)	Position/status	Chief Digital and Technology Officer	
c)	Initial notification/ amendment	Initial notification	

c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted	
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W2044
b)	Nature of the transaction	The number of ADSs vesting on awards granted in 2021 under the Company's 2017 Performance Share Plan
c)	Price(s) and volume(s)	Price(s)
		Volume(s)
		\$0.00
		5,383
d)	Aggregated information	N/A (single transaction)
	Aggregated volume	
	Price	
e)	Date of the transaction	2024-02-09
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	Shobie Ramakrishnan
b)	Position/status	Chief Digital and Technology Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted	
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W2044
b)	Nature of the transaction	The sale of ADSs to meet tax liabilities for the vesting of awards granted in 2021 under the Company's 2017 Performance Share Plan
c)	Price(s) and volume(s)	Price(s)
		Volume(s)
		\$41.84
		2,894
d)	Aggregated information	N/A (single transaction)

	Aggregated volume Price	
e)	Date of the transaction	2024-02-09
f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/person closely associated with them ('PCA')					
a)	Name	David Redfern				
b)	Position/status	President, Corporate Development				
c)	Initial notification/ amendment	Initial notification				
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a)	Name	GSK plc				
b)	LEI	5493000HZTVUYLO1D793				
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted					
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63				
b)	Nature of the transaction	The number of Ordinary Shares vesting on awards granted in 2021 under the Company's 2017 Performance Share Plan				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>£0.00</td> <td>161,385</td> </tr> </tbody> </table>	Price(s)	Volume(s)	£0.00	161,385
Price(s)	Volume(s)					
£0.00	161,385					
d)	Aggregated information Aggregated volume Price	N/A (single transaction)				
e)	Date of the transaction	2024-02-09				
f)	Place of the transaction	N/A				

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	David Redfern
b)	Position/status	President, Corporate Development
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793

3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted					
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63				
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2021 under the Company's 2017 Performance Share Plan				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>£16.6055</td> <td>75,851</td> </tr> </tbody> </table>	Price(s)	Volume(s)	£16.6055	75,851
Price(s)	Volume(s)					
£16.6055	75,851					
d)	Aggregated information Aggregated volume Price	N/A (single transaction)				
e)	Date of the transaction	2024-02-09				
f)	Place of the transaction	London Stock Exchange (XLON)				

1.	Details of PDMR/person closely associated with them ('PCA')					
a)	Name	Regis Simard				
b)	Position/status	President, Global Supply Chain				
c)	Initial notification/ amendment	Initial notification				
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a)	Name	GSK plc				
b)	LEI	5493000HZTVUJYLO1D793				
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted					
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63				
b)	Nature of the transaction	The number of Ordinary Shares vesting on awards granted in 2021 under the Company's 2017 Performance Share Plan				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>£0.00</td> <td>133,024</td> </tr> </tbody> </table>	Price(s)	Volume(s)	£0.00	133,024
Price(s)	Volume(s)					
£0.00	133,024					
d)	Aggregated information Aggregated volume Price	N/A (single transaction)				
e)	Date of the transaction	2024-02-09				
f)	Place of the transaction	N/A				

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Regis Simard	
b)	Position/status	President, Global Supply Chain	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2021 under the Company's 2017 Performance Share Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£16.6055	62,522
d)	Aggregated information	N/A (single transaction)	
	Aggregated volume Price		
e)	Date of the transaction	2024-02-09	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Phil Thomson	
b)	Position/status	President, Global Affairs	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	The number of Ordinary Shares vesting on awards granted in 2021 under the Company's 2017 Performance Share Plan	

c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£0.00	73,728
d)	Aggregated information Aggregated volume Price	N/A (single transaction)	
e)	Date of the transaction	2024-02-09	
f)	Place of the transaction	N/A	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Phil Thomson	
b)	Position/status	President, Global Affairs	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVJYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2021 under the Company's 2017 Performance Share Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£16.6055	34,653
d)	Aggregated information Aggregated volume Price	N/A (single transaction)	
e)	Date of the transaction	2024-02-09	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Deborah Waterhouse	
b)	Position/status	CEO, ViiV Healthcare and President, GSK Global Health	
c)	Initial notification/ amendment	Initial notification	

	2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
	3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	The number of Ordinary Shares vesting on awards granted in 2021 under the Company's 2017 Performance Share Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£0.00	94,120
d)	Aggregated information	N/A (single transaction)	
	Aggregated volume		
	Price		
e)	Date of the transaction	2024-02-09	
f)	Place of the transaction	N/A	

	1. Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Deborah Waterhouse	
b)	Position/status	CEO, ViiV Healthcare and President, GSK Global Health	
c)	Initial notification/ amendment	Initial notification	
	2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
	3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2021 under the Company's 2017 Performance Share Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£16.6055	44,237
d)	Aggregated information	N/A (single transaction)	
	Aggregated volume		
	Price		

	PRICE	
e)	Date of the transaction	2024-02-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')					
a)	Name	Tony Wood				
b)	Position/status	Chief Scientific Officer				
c)	Initial notification/ amendment	Initial notification				
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a)	Name	GSK plc				
b)	LEI	5493000HZTVUYLO1D793				
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted					
a)	Description of the financial instrument	Ordinary Shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63				
b)	Nature of the transaction	The number of Ordinary Shares vesting on awards granted in 2021 under the Company's 2017 Performance Share Plan				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>£0.00</td> <td>24,473</td> </tr> </tbody> </table>	Price(s)	Volume(s)	£0.00	24,473
Price(s)	Volume(s)					
£0.00	24,473					
d)	Aggregated information Aggregated volume Price	N/A (single transaction)				
e)	Date of the transaction	2024-02-09				
f)	Place of the transaction	N/A				

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	Tony Wood
b)	Position/status	Chief Scientific Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted	

a)	Description of the financial instrument	Ordinary Shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2021 under the Company's 2017 Performance Share Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£16.6055	11,503
d)	Aggregated information	N/A (single transaction)	
	Aggregated volume Price		
e)	Date of the transaction	2024-02-09	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Victoria Whyte	
b)	Position/status	Company Secretary	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUJYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	The number of Ordinary Shares vesting on awards granted in 2021 under the Company's 2017 Performance Share Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£0.00	9,456
d)	Aggregated information	N/A (single transaction)	
	Aggregated volume Price		
e)	Date of the transaction	2024-02-09	
f)	Place of the transaction	N/A	

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	Victoria Whyte

b)	Position/status	Company Secretary	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2021 under the Company's 2017 Performance Share Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£16.6055	4,445
d)	Aggregated information	N/A (single transaction)	
	Aggregated volume Price		
e)	Date of the transaction	2024-02-09	
f)	Place of the transaction	London Stock Exchange (XLON)	

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHSFWFIDELSEEE